AML

Gilteritinib showed improvement in overall survival in patients with relapsed or refractory FLT3 mutation-positive acute myeloid leukemia compared with chemotherapy, meeting the primary end point of the phase 3 COMMODORE confirmatory trial.

Curtis Lachowiez, MD, discusses the interim analysis of the phase 1b/2 study of venetoclax in combination with standard intensive acute myeloid leukemia induction plus consolidation therapy with the FLAG-IDA regimen as treatment of patients with newly diagnosed or relapsed/refractory AML

The first patient with acute myeloid leukemia in a phase 2 trial of the MultiTAA-specific T cell, MT-401 followed stem-cell transplant has been dosed with the agent, according to a press release by Marker Therapeutics, Inc.

Sergio Giralt, MD, discusses the current unmet medical needs for patients with relapsed/refractory acute myeloid leukemia.

The FDA granted Orphan Drug designation to first-in-class LSD1 inhibitor iadademstat, for the treatment of patients with acute myeloid leukemia.

Targeted radioimmunotherapy to the marrow with apamistamab conditioning therapy led to high rates of allogeneic hematopoietic stem cell transplant in patients with active, relapsed, or refractory acute myeloid leukemia, according to interim data from the phase 3 SIERRA trial.

Five-year follow-up data from the phase 3 CLTR0310-301 clinical trial shows continued OS benefit with the novel agent CPX-351 in acute myeloid leukemia subgroups.

A phase 1 study is the first to demonstrate that JSP191 is safe and effective in older patients with MRD-positive acute myeloid leukemia or myelodysplastic syndrome who are undergoing nonmyeloablative allogeneic hematopoietic cell transplantation.

Danielle Hammond, MD, discusses the results from a retrospective review of patients with acute myeloid leukemia treated over the last 6 years with a combination of venetoclax and either decitabine or azacitadine.

Andrew Wei, MBBS, PhD, discusses the results from the phase 3 QUAZAR AML-001 Maintenance Trial of CC-486 for patients with acute myeloid leukemia in the first remission after intensive chemotherapy.

Tapan M. Kadia, MD, discusses the treatment options for patients with newly diagnosed acute myeloid leukemia.

Ten-year overall survival is low among patients with acute myeloid leukemia , but an analysis demonstrated that survival is shorter for older patients treated with chemotherapy alone, according to published findings.

The FDA lifted the partial clinical hold that was placed on a phase 2 study of MT-401 as treatment of patients with post-transplant acute myeloid leukemia.

An Independent Data Monitoring Committee has recommended the pivotal phase 3 SIERRA study continue as planned to full enrollment of 150 patients based on the findings from a pre-planned ad hoc interim analysis of the study.

In a phase 1b clinical trial presented during the 2020 American Society of Hematology Annual Meeting, investigators sought to determine the efficacy and safety of the novel TIM-3–targeting IgG4 antibody sabatolimab in combination with hypomethylating agents as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.

Andrew M. Brunner, MD, shares his key take home message from a phase 1b clinical trial investigating sabatolimab as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.

A review by an Independent Data Monitoring Committee determined that combination of gilteritinib plus azacitidine would not likely improve overall survival compared with azacitidine alone in patients newly diagnosed FLT3-positive acute myeloid leukemia who were ineligible for intensive induction chemotherapy, missing the primary end point of the phase 3 LACEWING clinical trial.

The FDA granted a Fast Track designation to devimistat for the treatment of patients with acute myeloid leukemia.

Treatment with higher doses of CPX-351 in younger patients with newly diagnosed high-risk or secondary acute myeloid leukemia was significantly associated with prolonged hematologic recovery times during induction cycles 1 and 2.

The most important factor associated with poor survival among patients below 60 years of age with acute myeloid leukemia was self-reported black race in a SEER analysis.

In patients with acute myeloid leukemia and myelodysplastic syndrome, treatment with sabatolimab administered at 200 mg every 2 weeks and 800 mg every 4 weeks demonstrated similar pharmacokinetic activity, according to findings from a dose-selection and dose-response analysis presented during the 2020 American Society of Hematology Annual Meeting.

Treatment with a novel tri-specific natural killer cell engager agent led to natural killer cell proliferation across dose levels in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia.

Azacitidine administered orally to patients with acute myeloid leukemia demonstrated significant improvements in overall survival and relapse-free survival while sustaining the health-related quality of life compared with placebo.

The addition of the oral selective RARα agonist SY-1425 to azacitidine induced clinical activity as treatment of patients with heavily pretreated relapsed/refractory acute myeloid leukemia with RARA positivity.

Significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia in the Chicago metropolitan area were seen with census tract socioeconomic status information.